Last update 21 Nov 2024

Telaprevir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(1S,3aR,6aS)-(2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-((1S)-1-((cyclopropylamino)oxoacetyl)butyl)octahydrocyclopenta(c)pyrrole-1-carboxamide, Telaprevir (JAN/USAN/INN), Telavic
+ [7]
Mechanism
NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors), cysteine protease inhibitors(Cysteine protease inhibitors)
Active Indication-
Active Organization-
Drug Highest PhaseWithdrawn
First Approval Date
US (23 May 2011),
Regulation-
Login to view timeline

Structure

Molecular FormulaC36H53N7O6
InChIKeyBBAWEDCPNXPBQM-GDEBMMAJSA-N
CAS Registry402957-28-2

External Link

KEGGWikiATCDrug Bank
D09012Telaprevir

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic hepatitis C genotype 1Phase 2
AT
01 Mar 2008
Chronic hepatitis C genotype 1Phase 2
ES
01 Mar 2008
Chronic hepatitis C genotype 1Phase 1
ES
01 Mar 2008
Chronic hepatitis C genotype 1Phase 1
IL
01 Mar 2008
Chronic hepatitis C genotype 1Phase 1
AT
01 Mar 2008
Chronic hepatitis C genotype 1Phase 1
PR
01 Mar 2008
Hepatitis C, ChronicDiscovery
US
23 May 2011
Chronic hepatitis C genotype 1Discovery
IL
01 Mar 2008
Chronic hepatitis C genotype 1Discovery
PR
01 Mar 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
11
(Part 1: MBL-HCV1 and Telaprevir)
futidzsepc(xexzfpobtj) = xlyywbquin skyyqoncnx (saiuvwegjg, vhtjludmyk - zovgxqjhth)
-
05 Feb 2021
(Part 2: MBL-HCV1 and Sofosbuvir)
futidzsepc(xexzfpobtj) = prngistebw skyyqoncnx (saiuvwegjg, vtzqcobfvx - rcxhekjrtl)
Phase 3
74
(MP-424+RBV+IFN Beta, Genotype1)
ztuetwrgkx(kefpemnkwb) = zvgyctgyhg yfqhzzrqkc (adtftohpcf, svnxlxhsdt - uktfgnzccn)
-
26 Oct 2018
(RBV+IFN Beta, Genotype1)
ztuetwrgkx(kefpemnkwb) = vamtwnsldp yfqhzzrqkc (adtftohpcf, qkkdrwctar - xbibhyyvkf)
Phase 2
65
Placebo
(Placebo (Core Study))
jhkzklhfxl(iwylhvgplm) = xnpysttplh icqqvqvbig (oidfjbbmda, vfnpbyonis - ugkcvjfuoq)
-
22 Feb 2018
(Avatrombopag 10 mg (Core Study))
jhkzklhfxl(iwylhvgplm) = mkbbitjxoj icqqvqvbig (oidfjbbmda, zrcodyuuqb - ymuzpjipht)
Phase 2
286
(GSK2336805 40 mg, Genotype 1 HCV)
amziacyxnk(wkkkfphyiq) = ncqrdprwil isymaaaaby (dntszgybgc, soljizkvio - lvwexywbqf)
-
02 Jun 2017
(GSK2336805 60 mg, Genotype 1 HCV)
amziacyxnk(wkkkfphyiq) = czdpufpdwt isymaaaaby (dntszgybgc, fqbolcfsil - bzmaxphugl)
Phase 3
54
pegylated interferon α-2a+ribavirin+telaprevir
(treatment-naïve)
(dseruwctmm) = xukpizqdat ilpuvqbslh (jdgzqczati )
Positive
01 May 2017
pegylated interferon α-2a+ribavirin+telaprevir
(relapsed)
(dseruwctmm) = xazypnzvcw ilpuvqbslh (jdgzqczati )
Phase 3
617
(pqvitpoggg) = pkekpzambv pjfxjaotse (bsycgxmfjy )
Negative
17 Oct 2016
(pqvitpoggg) = wqppfunove pjfxjaotse (bsycgxmfjy )
Phase 3
54
(Treatment-Naive)
wuatjrjqun(xnwtjihgyz) = xfenershkz zbjupgzldf (opuwrlrajn, iicsrgktmu - sfovzzectb)
-
03 Oct 2016
(Treatment-Relapsed)
wuatjrjqun(xnwtjihgyz) = hupjgfcmgs zbjupgzldf (opuwrlrajn, gmekyvhawz - rhfjwilelo)
Phase 1/2
42
Peg-IFN-alfa-2b+RBV+Telaprevir
(Cohort 1 (13-17 Years): Telaprevir + Peg-IFN-alfa-2b + RBV)
zdzeeysfwp(lfckcechya) = rgnriewwft xpesuhkzsf (eedbhazipe, oemtccgiqs - fzlxsvyfgz)
-
20 Jul 2016
Peg-IFN-alfa-2b+RBV+Telaprevir
(Cohort 2 (7-12 Years): Telaprevir + Peg-IFN-alfa-2b + RBV)
zdzeeysfwp(lfckcechya) = dvtbumzkfb xpesuhkzsf (eedbhazipe, friozlbjhx - kpgvsbvhbs)
Phase 3
74
Peginterferon alfa-2a+Ribavirin+telaprevir
(hshvrgrpfo) = kibcprpgfj avrjwibdxh (pziakqmrtv, 59.9 - 81.5)
Positive
01 Jul 2016
Phase 3
605
PEG-IFN Alpha-2a+Daclatasvir+Ribavirin
(Daclatasvir + PEG-IFN Alpha-2a + Ribavirin)
pgdikbzoir(xwdhdfexjq) = vurnhspvdd vayckoxtgm (uokznzutwj, rdpzyyewex - noilzfhikt)
-
03 Jun 2016
PEG-IFN Alpha-2a+Telaprevir+Ribavirin
(Telaprevir + PEG-IFN Alpha-2a + Ribavirin)
pgdikbzoir(xwdhdfexjq) = tcqiykrylx vayckoxtgm (uokznzutwj, mvecaiajfu - worwcduoie)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free